May 13, 2026
A review of more than 200 studies linked up to a third of dementia cases to diseases outside the brain. Trials and broader evidence also support multi-domain prevention strategies.
May 05, 2026
Animal health markets are projected to expand in 2026, led by animal biotechnology at $34.6 billion to $36.19 billion and continued growth in veterinary antibiotics. Demand is being driven by companion animal care, livestock health, biologics R&D, and tighter oversight of antibiotic use.
May 04, 2026
Cynata raised $1.5 million through a placement at $0.25 a share ahead of Phase 3 osteoarthritis and Phase 2 aGvHD trial readouts due in May and June 2026. Its aGvHD study has completed the 100-day primary evaluation period for all 65 participants.
Apr 13, 2026
The healthcare 3D printing market is projected to reach $14.6 billion by 2033, while the bioinks market is anticipated to reach USD 683.6 million. Growth is tied to personalised medical solutions, tissue engineering, drug discovery, and advances in biomaterials.
Mar 09, 2026
Five intra-articular gene therapy platforms for knee osteoarthritis are in human trials in the US, while India prepares regulatory guidelines for mRNA, gene and cell therapies to accelerate innovation.
Mar 05, 2026
Semaglutide reduced osteoarthritis progression in obese mice through metabolic reprogramming of cartilage cells, independent of weight loss effects, according to research published in Cell Metabolism.
Feb 27, 2026
Research identifies orphan nuclear receptor SHP (NR0B2) as a novel regulator of osteoarthritis progression, demonstrating that it protects cartilage by inhibiting IKKβ/NF-κB signaling and reducing matrix-degrading enzyme expression in chondrocytes.
Feb 20, 2026
The European Commission has approved a new 7.2 mg once-weekly maintenance dose of Wegovy (semaglutide injection) for adults with obesity, providing physicians with an additional treatment option for patients requiring further weight reduction after the 2.4 mg dose.
Feb 21, 2026
New research reveals semaglutide may directly repair cartilage in osteoarthritis patients, while a separate study raises concerns about SNAC, an ingredient used in oral semaglutide formulations, and its effects on gut health.
Feb 14, 2026
Researchers from Stanford Medicine developed an injection that reprograms cells to regrow cartilage by blocking the protein 15-PGDH, offering potential treatment for osteoarthritis from aging or injury.